RecruitingPhase 3NCT07794579A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 ObesitySponsor: Eli Lilly and CompanyAustin, TX · Brownsville, TX · Dallas, TX · +77 more sites
RecruitingPhase 3NCT06937086Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b StudySponsor: Eli Lilly and CompanySan Antonio, TX · Tyler, TX · +34 more sites
RecruitingPhase 3NCT06937099Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or OverweightSponsor: Eli Lilly and CompanySan Antonio, TX · Tyler, TX · +32 more sites
Not yet recruitingPhase 3NCT07881432A Study of EloraTZP in Adult Participants With Obesity Without Type 2 DiabetesSponsor: Eli Lilly and CompanyBellaire, TX · Dallas, TX · +52 more sites
Not yet recruitingPhase 3NCT07881458A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 DiabetesSponsor: Eli Lilly and CompanyAustin, TX · Fort Worth, TX · Houston, TX · +22 more sites